Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients (REaCT-TAPS)
Early-stage Breast Cancer, Pain Syndrome

About this trial
This is an interventional treatment trial for Early-stage Breast Cancer
Eligibility Criteria
Inclusion Criteria:
Patients receiving docetaxel-based chemotherapy (Docetaxel 75mg/m2 and cyclophosphamide once every 21 days; or Docetaxel 75mg/m2 and carboplatin and trastuzumab once every 21 days or Fluoro-uracil, epirubicin and cyclophosphamide for 3 cycles once every 21 days, then docetaxel 100mg/m2 once every 21 days; or Adriamycin and cyclophosphamide for 3 cycles, then docetaxel 100mg/m2 once every 21 days) for early stage breast cancer.
- English literacy and ability to complete questionnaire
- ≥19 years of age
Exclusion Criteria:
- Contraindication to dexamethasone
- Unable to give informed consent
- Prior receipt of taxane-based chemotherapy
- Patient has a significant emotional or psychiatric disorder that in the opinion of the investigator precludes study entry.
Sites / Locations
- Southlake Regional Cancer Centre
- The Ottawa Hospital Cancer Centre
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
dexamethasone tapering dose
dexamethasone physician choice
standard dexamethasone pre-medication (8mg B.I.D x 3 days commencing the day before chemotherapy) then 4mg 1x/d for 2 days followed by 2mg 1x/d for 2 days
standard dexamethasone pre-medication (i.e. 8mg B.I.D x 3 days commencing the day before chemotherapy) then physician choice interventions